|
| Exchange Disseminated Time | Citigroup Global Markets India Private Limited ("Manager to the Offer"), on behalf of Sun Pharmaceutical Industries Limited ("Sun Pharma" / "Acquirer"), has informed this Post Offer Announcement to the Shareholders of Zenotech Laboratories Limited (“Zenotech” / “Target Company”), pursuant to Regulation 18(12) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 (“SEBI (SAST) Regulations”) in respect of the open offer (“Offer”) for acquisition of up to 9,693,332 (Nine Million Six Hundred Ninety Three Thousand Three Hundred Thirty Two) fully paid up
equity shares (“Shares”) representing 28.16% of the fully diluted share capital of the Target Company”), pursuant to and in compliance with Regulations 3(1), 4 and 5(1) of the SEBI (SAST) Regulations.
This Announcement should be read in continuation and in conjunction with the Public Announcement dated April 11, 2014 (“PA”), the Detailed Public Statement with respect to the aforementioned Offer dated March 30, 2015 (“DPS”), the Letter of Offer dated June 18, 2015 (“Letter of Offer”), and the Offer Opening Advertisement published on June 29, 2015. |
|
|